Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.

Abstract

Cutaneous T-cell lymphomas, including mycosis fungoides and Sezary syndrome, are often responsive to treatment, but current therapies have not been shown to increase survival, and in advanced stages, durable remissions are hard to achieve. We present a patient who was initially misdiagnosed with psoriasis and, 16 years later, was diagnosed with mycosis fungoides. Denileukin diftitox was used as a tumor debulking agent to give a partial response that was further improved with a combination of systemic interferon/oral bexarotene and skin-directed psorlen plus UV-A. The purpose of this case report is to show the value of sequential combination therapy for improving overall response.

• Authors: Rakhshandra Talpur, Madeleine Duvic
• Journal: Clinical lymphoma & myeloma (Clin Lymphoma Myeloma) Vol. 6 Issue 6 Pg. 488-92 (May 2006) ISSN: 1557-9190 [Print] United States
• PMID: 16796781 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Anticarcinogenic Agents
• Antineoplastic Agents
• Diphtheria Toxin
• Interleukin-2
• Recombinant Fusion Proteins
• Tetrahydronaphthalenes
• denileukin diftitox
• Bexarotene

Topics

• Administration, Oral
• Anticarcinogenic Agents (administration & dosage, therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Bexarotene
• Combined Modality Therapy
• Diphtheria Toxin (therapeutic use)
• Female
• Humans
• Interleukin-2 (therapeutic use)
• Middle Aged
• Mycosis Fungoides (drug therapy, radiotherapy)
• PUVA Therapy
• Recombinant Fusion Proteins (therapeutic use)
• Tetrahydronaphthalenes (administration & dosage, therapeutic use)
• Treatment Outcome